Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers

BACKGROUND: Besides improving glucose control, sodium-glucose co-transporter 2 inhibition with dapagliflozin reduces blood pressure, body weight and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes (T2DM). The parameter response efficacy (PRE) score was developed to predict h...

Descripción completa

Detalles Bibliográficos
Autores principales: Idzerda, Nienke M A, Stefansson, Bergur V, Pena, Michelle J, Sjostrom, David C, Wheeler, David C, Heerspink, Hiddo J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473803/
https://www.ncbi.nlm.nih.gov/pubmed/31005993
http://dx.doi.org/10.1093/ndt/gfz064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473803/
https://www.ncbi.nlm.nih.gov/pubmed/31005993
http://dx.doi.org/10.1093/ndt/gfz064

Ejemplares similares